Patent application number | Description | Published |
20100100334 | LIPOPROTEIN INSULIN RESISTANCE INDEXES AND RELATED METHODS, SYSTEMS AND COMPUTER PROGRAMS FOR GENERATING SAME - Methods, reports and systems for generating insulin resistance indexes for assessing decreased insulin sensitivity and/or levels of insulin resistance using a plurality of different measured lipoprotein particle parameters. | 04-22-2010 |
20110295517 | NMR ANALYZERS FOR CLINICAL EVALUATION OF BIOSAMPLES - The clinical analyzers automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites. | 12-01-2011 |
20130289884 | PROTECTIVE HDL PARTICLE NUMBER EVALUATIONS - Embodiments of the invention are directed to improved discrimination of protective (anti-atherogenic) HDL from atherogenic or non-protective (NP) HDL. The methods, systems and computer program products determine protective high density lipoprotein particle (HDL-P) numbers. The methods include obtaining concentration measurements of at least twenty subpopulations of HDL-P subclasses in a blood plasma or serum sample and calculating a protective HDL-P number using (i) a defined subset of the obtained HDL-P concentration measurements or (ii) a zero or defined weighting factor below 1 for HDL-P concentration measurements for HDL subclasses associated with particle sizes above about 11 nm. | 10-31-2013 |
20130289885 | CHD RISK STRATIFICATION EVALUATIONS FOR SUBJECTS WITH HIGH LEVELS OF LARGE HDL -P - Embodiments of the invention are directed to methods, systems and computer programs that provide improved risk stratification for people having elevated large HDL-P using at least one defined HDL risk interaction parameter. | 10-31-2013 |
20130325353 | NMR QUANTIFICATION OF TMAO - A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM. | 12-05-2013 |
20130328561 | NMR MEASUREMENTS OF GLYCA - Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra. | 12-12-2013 |
20130332082 | MULTI-PARAMETER DIABETES RISK EVALUATIONS - Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject. | 12-12-2013 |
20150149094 | NMR QUANTIFICATION OF TMAO - A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM. | 05-28-2015 |